Authors:  Michelle Edwards -May 12, 202

Was the clinical trial for Pfizer’s mRNA-based gene-therapy “vaccine” fraudulent? Many are asking that question, and rightly so. Documents released in Nov. 2021 by the FDA as part of the court-mandated document dump show evidence of clinical trial enrollment at one particular trial site happening rapidly and just in time to meet the safety deadline for the FDA’s VRBPAC meeting on Dec. 10, 2020, to discuss Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 jab in individuals 16 and older. Presented on Twitter by Jikkyleaks, the report has raised critical questions.  

The allegedly suspicious-looking clinical trial data surrounds “the biggest recruiter by far,” site 1231 (site 4444 was assigned site id 1231) in Argentina. Adding to the confusion, in five short days before the safety deadline (including a Sunday, 9/27/20), the trial recruited 1,275 of the 4,501 people using site number 4444. In just three weeks, the site recruited 4,501 patients—10% of the entire trial at one site. Overall, Pfizer rapidly recruited roughly 44,000 people for their trial, which took place at 152 locations worldwide and was overseen by numerous investigators, including Dr. Fernando Polack, who led the Argentinian study at Hospital Militar Central. 

As pointed out by Steve Kirsch, Polack is the Scientific Director of the INFANT Foundation in Buenos Aires. The Vanderbilt-affiliated foundation gives participants the opportunity to conduct biomedical translational research or pediatric rotations at hospitals and medical centers in Buenos Aires. Polack coordinates 26 hospitals in Argentina involving 467 doctors who were instantly recruited into the Pfizer trial. Kirsch said the “new data on Site 1231/4444 looks too good to be true,” but he also noted that all things considered, “it’s quite possible they pulled it off” and coordinated the trial in record time. Noting the infrastructure already in place at Hospital Militar Central, Kirsch referenced an article from Sept. 10, 2020, adding: 

“So if all 26 hospitals participated fully then that’s 57 patients per week per hospital which is possible if the sites have done this before and have a coordination framework for getting all 26 sites up and running at the same time. This means that everyone who was doing something else dropped what they were doing to switch over to the trial all at the same time.”

Still, as Professor Norman Fenton of Queen Mary London University pointed out, the circumstances surrounding the trial are remarkable. Fenton refers to a Substack two-part series on the Site 1231/4444 documents by el gato malo, who wrote that it is “basically impossible,” no matter who you are, to run a clinical trial this quickly. Malo added, “if this really happened, it would be a wonder of the world, and they should publish the process with pride and win 27 different prizes for it.” Malo continued, saying:

“They claim to have enrolled seven days a week for three weeks with zero gaps. Each patient requires a 250-page case report form. The lead investigator seems to have been Fernando Polack.

If indeed, the best way to get things done is to give them to busy people, then this was a great choice because, from the look of things, Fernando is one busy fellah and connected up the wazoo to boot. He also works with Vanderbilt, the FDA, and the Infant Foundation, funded by the Gates Foundation and the NIH.”

Kirsch remarked that Polack is the first author in the New England Journal of Medicine’s (NEJM) article on the Pfizer “vaccine,” titled “Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine.” Interestingly, in the disclosure form for the authors of the NEJM paper, Polack reported receiving personal fees from companies including Pfizer, Janssen, Regeneron, and Merck. Likewise, he disclosed grants from Novavax, Inc. Kirsch (who shared a video on Polack, but noticed no real “smoking gun”) highlighted a few exerts from the Dec. 31, 2020 paper, including:

“About 5,800 volunteers were enrolled, half getting the active vaccine. This is almost 4 times more than the next largest centre in this trial. Amazingly 467 doctors were almost instantly signed up and trained as assistant investigators in the study. Fernando was in command as Pfizer’s Principal Investigator.

Neither Augusto’s pericardial effusion, nor another volunteer’s penile vein thrombosis, appear to have found their way into the reported side effects of this trial.”